David A. Siegel Chinook Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $522,480 - $1.08 Million	-28,000 Reduced 13.03%	186,880 $7.18 Million
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $475,813 - $592,280	-22,100 Reduced 9.33%	214,880 $4.97 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $152,766 - $224,270	-8,200 Reduced 3.34%	236,980 $6.21 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $1.94 Million - $2.59 Million	110,700 Added 82.32%	245,180 $4.82 Million
Q2 2022 Aug 15, 2022	SELL	$12.59 - $18.8 $50,863 - $75,952	-4,040 Reduced 2.92%	134,480 $2.35 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $2.14 Million - $2.98 Million	-178,400 Reduced 56.29%	138,520 $2.27 Million
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $671,332 - $1.06 Million	-62,800 Reduced 16.54%	316,920 $5.17 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $2.48 Million - $3.21 Million	215,800 Added 131.65%	379,720 $4.85 Million
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $1.01 Million - $1.41 Million	74,500 Added 83.31%	163,920 $2.32 Million
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $53,846 - $72,618	-3,800 Reduced 4.08%	89,420 $1.39 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $1.11 Million - $1.95 Million	93,220 New	93,220 $1.48 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.